| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 1. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | oxycodone/naloxone (Targinact®) |
| Formulation | 5 mg/2.5 mg, 10 mg/5 mg, 20 mg/10 mg and 40 mg/20 mg prolonged-release tablet |
| Reference number | 356 |
| Indication | Severe pain, which can be adequately managed only with opioid analgesics |
| Company | Napp Pharmaceuticals Ltd |
| BNF chapter | Central nervous system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 07/01/2009 |